Linden Advisors’s DA32 Life Science Tech Acquisition Corp DALS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-381,300
Closed -$3.91M – 407
2023
Q2
$3.91M Hold
381,300
– – 0.04% 196
2023
Q1
$3.86M Hold
381,300
– – 0.04% 204
2022
Q4
$3.8M Hold
381,300
– – 0.04% 239
2022
Q3
$3.7M Hold
381,300
– – 0.03% 278
2022
Q2
$3.7M Hold
381,300
– – 0.03% 295
2022
Q1
$3.7M Buy
+381,300
New +$3.68M 0.02% 386

Linden Advisors's DALS Position: Q3 2023 in Review

Linden Advisors sold out of DA32 Life Science Tech Acquisition Corp (DALS) in Q3 2023, closing a stake of 381,300 shares — an estimated $3.91M sold.

Linden Advisors first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $3.91M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

  • Linden Advisors reported no remaining DA32 Life Science Tech Acquisition Corp position as of Q3 2023 after selling out during the quarter.
  • Linden Advisors sold 381,300 DA32 Life Science Tech Acquisition Corp shares in Q3 2023, an estimated $3.91M.
  • Linden Advisors first reported a position in DA32 Life Science Tech Acquisition Corp in Q1 2022 and held it in 6 quarters.
  • Linden Advisors's DA32 Life Science Tech Acquisition Corp position peaked at $3.91M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp as of Q3 2023.

Based on Linden Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.